Cantor Fitzgerald Brokers Reduce Earnings Estimates for ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities research analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of ACADIA Pharmaceuticals in a research report issued to clients and investors on Thursday, February 27th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will post earnings per share of $0.15 for the year, down from their prior forecast of $0.24. Cantor Fitzgerald has a "Overweight" rating and a $28.00 price objective on the stock. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share.

Several other research analysts also recently commented on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 11th. They set a "hold" rating and a $22.00 price objective for the company. StockNews.com lowered ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday. Guggenheim downgraded ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. Needham & Company LLC reaffirmed a "buy" rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Finally, HC Wainwright reissued a "buy" rating and issued a $27.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Nine investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $24.00.

Remove Ads

ACADIA Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ:ACAD traded up $0.10 during midday trading on Friday, reaching $18.26. 1,585,711 shares of the company were exchanged, compared to its average volume of 2,731,195. The stock has a market cap of $3.04 billion, a PE ratio of 23.41 and a beta of 0.37. The business's fifty day moving average is $18.44 and its two-hundred day moving average is $16.88. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $24.27.

Institutional Trading of ACADIA Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Virtus Fund Advisers LLC bought a new position in shares of ACADIA Pharmaceuticals during the fourth quarter valued at approximately $39,000. R Squared Ltd bought a new position in ACADIA Pharmaceuticals in the 4th quarter valued at $47,000. GF Fund Management CO. LTD. purchased a new stake in ACADIA Pharmaceuticals in the fourth quarter worth $64,000. Quest Partners LLC lifted its position in shares of ACADIA Pharmaceuticals by 42.3% during the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company's stock worth $54,000 after purchasing an additional 1,047 shares during the last quarter. Finally, KBC Group NV boosted its stake in shares of ACADIA Pharmaceuticals by 67.0% during the fourth quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 2,044 shares during the period. Institutional investors own 96.71% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.